Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.

However, full survival data analysis identified longer median PFI in SLFN11 high patients of 14 months compared to 6 months in SLFN11 low patients, but differences did not reach statistical significance ( P = 0.0705, Fig. 4e ).

also in 111,027 other papers

Our findings demonstrate an interesting trend linking high SLFN11 expression with longer progression-free survival following olaparib that was independent of BRCA mutation, although sample sizes were limited and this finding did not extend to longer overall survival when BRCA status was accounted for.

also in 1,783 other papers